Pharmacologic approaches to reperfusion injury.
Willerson
J T
JT
Department of Cardiovascular Research Texas Heart Institute, Houston, USA.
D000241:Adenosine / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005609:Free Radicals / Q000378:metabolism; D006801:Humans; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000378:metabolism; D017682:Myocardial Stunning / Q000188:drug therapy; D009569:Nitric Oxide / Q000627:therapeutic use*; D019087:Selectins / Q000276:immunology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000911:Antibodies, Monoclonal; D000975:Antioxidants; D002121:Calcium Channel Blockers; D005609:Free Radicals; D019087:Selectins; D009569:Nitric Oxide; D000241:Adenosine